News

The expansion will take the company’s footprint from its current 90,000ft² to approximately 200,000 ft². The first phase will double the cGMP capacity. Tris has received five new

No treatment-associated adverse events were observed in either of the patients in the study during the ERC dosing procedure, which involves a series of intramuscular injections in the

The Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5mg) is the generic equivalent to Teva Women’s Health’s Plan B One-Step. The company plans to launch the product immediately. Plan

The companies also announced regulatory submission for FF/VI as asthma therapy in the European Union. FF/VI, which also includes the investigational LAMA/LABA combination umeclidinium bromide/vilanterol,VI monotherapy and MABA,

The collaboration focuses on late-phase research, recruiting for and monitoring of clinical trials, and post-market surveillance. The partnership aims at developing products that overcome obstructions in clinical research,

The randomized, double-blind, global studies will compare CB-315 (250 mg BID) with the active comparator oral vancomycin (125 mg QID). Each study is likely to enroll 608 eligible

The move follows the agency’s warning to the company over the repeated violations of cGMPs (current good manufacturing practices) and the Federal Food, Drug and Cosmetic Act. In

The Preventing Abuse of Cough Treatments (PACT) Act of 2012 is expected to prohibit the sale of over-the-counter (OTC) cough medicines containing dextromethorphan (DXM) to teens below the

Under the agreement, Vertellus will include its worldwide operations across Europe and Asia encompassing India and China . Vertellus Specialties global supply chain corporate director Hugh Mitchell said